SCHEMBL2755211

SCHEMBL2755211

Cc1ccc(-c2cc3ncc4cc(-c5ccccc5)c(=O)[nH]c4n3n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.49
RAB9A P51151 9/20 0.49
SMN1; SMN2 Q16637 8/20 0.49
KDM4E B2RXH2 8/20 0.49
ALDH1A1 P00352 8/20 0.49
HPGD P15428 6/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
GAA P10253 2/20 0.49
CYP2C19 P33261 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PARP1 P09874 1/20 0.46
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238085 0.89 KDM4E (0.46) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL237870 0.88 NPC1 (0.60) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL240253 0.88 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL237769 0.86 AURKA (0.46) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL237827 0.84 NPC1 (0.44) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL239224 0.83 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL236540 0.83 AURKA (0.38) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL237826 0.82 MET (0.38) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL237744 0.80 PLAT (0.40) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL238959 0.79 HPGD (0.40) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.